Overview
Omni orthopedic implants usually refer to devices and technologies developed by OMNI, also known in public records as OMNIlife Science or OMNI Orthopaedics. The clearest public record is in knee arthroplasty, particularly the Apex Knee system, the OMNI TiN Coated Apex Knee system, and the OMNIBotics robotic-assisted total knee arthroplasty platform.
For readers comparing orthopedic implant technologies, the main point is simple: “Omni” is not a generic implant category. It is a brand and regulatory history tied to specific knee, hip, navigation, and robotic-assisted surgical products, now commonly discussed within Corin’s implant and digital surgery portfolio.
This article summarizes what the public record shows, where the evidence is strongest, and what should be verified before making clinical, procurement, or product-comparison decisions.
What “Omni orthopedic implants” means
The phrase can be confusing because “Omni” appears in several related contexts. Older records associate OMNIlife Science with proprietary hip and knee implants. In knee replacement, the Apex Knee system is the implant family most often linked with OMNI. In robotic-assisted total knee arthroplasty, OMNIBotics is the associated surgical technology platform. Corin’s more recent materials also discuss ApolloKnee as a next-generation robotic-assisted platform.
The distinction matters. A knee implant is the device that remains in the body. A robotic or navigation system is a surgical enabling technology used during implantation. OMNIBotics does not make the implant itself “robotic”; it supports planning, bone resection guidance, alignment, and soft-tissue balancing during total knee arthroplasty.
The corporate timeline also matters. Corin announced a binding agreement to acquire US-based OMNI Orthopaedics on March 6, 2019, describing OMNI as a company with proprietary hip and knee implants and a robotic-assisted total knee replacement platform. Since that announcement, many public product references have placed OMNI-related knee technologies within the Corin ecosystem.
Key technologies linked to Omni implants
Apex Knee system
The Apex Knee system is the main implant family associated with Omni orthopedic implants in public FDA and product records. FDA 510(k) materials describe Apex Knee devices for total knee replacement, including primary and revision use under specified indications. These indications include non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid arthritis, correction of functional deformity, and revision procedures where other treatments or devices have failed.
Corin product materials describe Apex Knee as a primary total knee system focused on function, fit, and system versatility. Public materials also describe options across implant styles and fixation approaches, including cruciate-retaining and posterior-stabilized concepts, cemented and porous-coated fixation options, and revision-related components. In practical terms, “Apex Knee” is not a single universal component. It is a system family, with components selected according to anatomy, fixation needs, indication, and surgeon planning.
OMNI TiN Coated Apex Knee system
The OMNI TiN Coated Apex Knee system received an FDA 510(k) substantial equivalence decision on September 25, 2019 under K191765. The 510(k) summary describes the change as adding a thin titanium nitride coating to cobalt-chromium-molybdenum metal components. The stated purpose in the FDA summary was to substantially reduce release of cobalt-chromium-molybdenum metal ions into body fluids, bone, or soft tissues.
That statement should be read with its regulatory context. The same FDA summary states that no clinical studies were performed for that submission, and that the fundamental scientific technology, substrate materials, design, sterilization, packaging, and manufacturing methods were not changed. The public record supports the coating rationale and the non-clinical testing basis, but it should not be interpreted as proof of superior clinical outcomes for every patient.
OMNIBotics Knee System and BalanceBot
OMNIBotics is best understood as a robotic-assisted and computer-assisted navigation system for total knee arthroplasty. FDA 510(k) record K200888, with a decision date of June 27, 2020, describes the OMNIBotics Knee System as indicated for stereotaxic surgery to help the surgeon locate anatomical structures and align endoprostheses during total knee arthroplasty. The same record states that BalanceBot is indicated as a tool for adjustment of soft tissue and the femoral implant to reduce instability from flexion gap asymmetry.
The FDA summary describes a system that includes a station, software, an optical tracking system, a motorized bone cutting guide, and BalanceBot as an active knee spacer and ligament tensioning device. This is relevant because soft-tissue balance is one of the more demanding parts of total knee arthroplasty. Robotic planning and measured ligament tension can give the surgeon more quantitative information than manual assessment alone, although surgical judgment remains central.
Hip implant references
Although most search interest around Omni orthopedic implants centers on knees, FDA records also contain references to OMNI hip systems and related Corin hip products. Public 510(k) database results include Corin hip products such as Omni Mod hip system, Omni K1 and K2 hip systems, and Omni ceramic head references. These products should be researched by exact device name, catalogue number, and 510(k) record because hip and knee systems have different indications, materials, surgical workflows, and evidence bases.
Regulatory timeline and public record highlights
Regulatory records are not a substitute for clinical judgment, but they are essential for understanding whether a device is cleared for marketing, which indications were reviewed, and what limitations appear in public summaries. In the United States, many orthopedic implants and surgical navigation systems reach market through the FDA 510(k) process, which is based on substantial equivalence to predicate devices rather than the premarket approval pathway used for some higher-risk devices.
| Date or record | Product or event | Why it matters |
|---|---|---|
| March 6, 2019 | Corin announced an agreement to acquire OMNI Orthopaedics | Connects the OMNI implant and robotic-assisted knee portfolio to Corin’s broader orthopedic strategy. |
| September 25, 2019 | FDA K191765 for OMNI TiN Coated Apex Knee system | Documents substantial equivalence for a TiN-coated Apex Knee variant and describes the coating rationale and testing basis. |
| June 27, 2020 | FDA K200888 for OMNIBotics Knee System | Documents the robotic-assisted stereotaxic system and its support for OMNI Apex Knee and Corin Unity Knee implants. |
| April 2, 2021 | FDA K201611 for Apex Knee System | Documents an Apex Knee system clearance, including Class II knee prosthesis classifications and product codes listed in FDA records. |
| May 23, 2025 and July 2, 2025 | FDA Class II recall record for certain Apex Knee System units | The recall was initiated by the firm on May 23, 2025 and posted by FDA on July 2, 2025, with the stated reason involving loss of integrity in some nylon packaging pouches. |
The 2025 recall record needs careful reading. FDA listed the status as open and classified in the record updated August 25, 2026. The record identified 341 units in commerce and named affected model and serial numbers. The stated action instructed consignees to identify affected units on hand, quarantine them, return them to Corin, and notify relevant parties. This does not mean every Apex Knee device is affected, and it does not automatically mean an implanted device is unsafe. Recall relevance depends on exact model, serial, distribution, and patient-specific information.
What the clinical evidence suggests
The strongest evidence around Omni-related technologies is generally about surgical accuracy, alignment execution, and measured soft-tissue balancing. It is less definitive on long-term proof that every patient outcome is better. That is a common pattern in robotic-assisted arthroplasty research: technical precision can be measured earlier and more directly, while survivorship, revision rates, and patient-reported outcomes require longer follow-up and careful comparison. See also: Fixation.
A 2021 review of the OMNIBot platform reported that the system is an imageless, passive robotic platform used in total knee arthroplasty and that more than 30,000 TKAs had been performed with its assistance since 2007. The review concluded that the platform showed accuracy and consistency as a delivery tool, while also noting that patient-reported outcome data were limited. That balance is important. Precision is a real engineering and surgical objective, but patient satisfaction after knee replacement depends on many variables beyond component placement.
More recent published research continues to examine the value of ligament balancing. A prospective nonrandomized controlled trial discussed BalanceBot as an integrated robotic joint tensioning tool that applies prescribed force to the knee and measures medial and lateral gaps through the range of motion. A 2025 comparative study reported better reproduction of planned alignment and better one-year Oxford and Forgotten Joint scores in the OMNIBotics group than in a conventional group for the same prosthesis and operator. However, that study was retrospective, so it can support useful comparisons but does not remove the need for broader prospective evidence.
The cautious interpretation is that OMNIBotics and related balancing tools may help surgeons quantify alignment and gap balance during total knee arthroplasty. The evidence is less settled on whether those technical advantages consistently translate into durable clinical superiority across patient groups, hospitals, implant configurations, and surgeon experience levels.
How to evaluate Omni implant information responsibly
Anyone researching Omni orthopedic implants should avoid treating the brand name as enough information. Orthopedic systems can include many components, sizes, coatings, inserts, stems, augments, instruments, and software versions. A meaningful comparison requires the exact device identity.
- Confirm the trade name, such as Apex Knee, OMNI TiN Coated Apex Knee, OMNIBotics, ApolloKnee, or a specific OMNI hip system.
- Check the FDA 510(k) number or other local regulatory record, especially when comparing US, UK, EU, or Australian availability.
- Separate implant claims from robotic workflow claims; the implant and the enabling technology have different evidence questions.
- Review indications for use, fixation type, material and coating information, and contraindications in the applicable instructions for use.
- Verify recall status by model and serial number rather than assuming a recall applies to an entire brand family.
- Evaluate clinical evidence by study design, sample size, follow-up length, comparator group, and whether outcomes were patient-reported or mainly radiographic.
For hospitals and procurement teams, the decision is also operational. Robotic-assisted TKA may require capital investment, staff training, workflow adaptation, data governance review, and service support. For surgeons, the question is whether the system supports their alignment philosophy and soft-tissue balancing approach. For patients, the most relevant discussion is usually not whether one brand is fashionable, but whether the surgeon can explain why a specific implant and workflow fit the patient’s anatomy, diagnosis, activity expectations, and risk profile.
Industry implications
Omni-related technologies reflect a broader direction in orthopedic implants: the implant is increasingly linked to planning software, intraoperative measurement, robotics, and postoperative data. The value proposition is no longer only metallurgy, polyethylene design, or component geometry. It also includes how accurately the surgeon can place the component, how the soft tissues are balanced, and how procedure data may inform future care pathways.
At the same time, the industry needs discipline in how claims are framed. Robotic-assisted knee replacement is not automatically better simply because it is robotic. Coated implants are not automatically appropriate for every patient because they use a ceramic-like surface coating. A 510(k) clearance is not the same as a head-to-head clinical superiority trial. Recalls must be interpreted by specific device, lot, model, and failure mode.
The practical conclusion is that Omni orthopedic implants, especially Apex Knee and OMNIBotics-linked workflows, occupy an important place in the move toward data-supported and robotic-assisted arthroplasty. They should be evaluated through verified regulatory records, exact device identification, clinical evidence quality, and local surgical experience.
Frequently asked questions
Are Omni orthopedic implants the same as OMNIBotics?
No. Omni orthopedic implants usually refer to implant systems such as Apex Knee or certain OMNI hip products. OMNIBotics is a robotic-assisted navigation and balancing platform used during total knee arthroplasty. The implant remains in the body; the robotic system assists the surgical workflow.
Is the Apex Knee system FDA approved?
Public FDA records list Apex Knee and related OMNI devices through 510(k) clearances, meaning FDA determined substantial equivalence for the reviewed indications and device characteristics. In precise regulatory language, these are generally described as FDA-cleared devices rather than PMA-approved devices.
Does TiN coating prove better outcomes?
No. FDA materials for the OMNI TiN Coated Apex Knee system describe the coating, its intended purpose, and non-clinical testing. The public 510(k) summary also states that no clinical studies were performed for that submission. Clinical benefit should therefore be discussed cautiously and in context.
Was there an Apex Knee recall?
Yes. FDA posted a Class II recall record on July 2, 2025 for certain Apex Knee System units, with the stated issue involving nylon packaging pouch integrity. The record identified affected model and serial numbers and listed 341 units in commerce. The key point is specificity: recall relevance depends on the exact device and serial information.
Are Omni orthopedic implants still used today?
Public device databases and Corin product materials continue to show Apex Knee and related technologies in current orthopedic discussions, but availability can vary by country, hospital, surgeon preference, and product configuration. Exact availability should be verified through official product labeling and local regulatory status.